Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of S-1 and capecitabine plus oxaliplatin on coronary artery blood flow in metastatic gastrointestinal adenocarcinoma
2013-003976-11Phase 2Terminated
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastrointestinal tract adenocarcinoma comparing S-1 (tegafur) + oxaliplatin with Capecitabine + oxaliplatin (2 arms). Primary endpoint: Frequency of subclinical coronary artery dysfunction compared with baseline. Started Dec 2013; status: terminated.
02
Drugs
tegafurcapecitabineoxaliplatin
03
Conditions
gastrointestinal tract adenocarcinoma
Beyond the preview
Go deeper on 2013-003976-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003976-11.